CYTOKINETICS INCORPORATED - COMMON STOCK

Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HCM Society Scientific Sessions

30 Sep 2022 10:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Call for Proposals for Its Fifth Annual Communications Grant Program

28 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Upcoming Presentations at the 2022 Inaugural HCM Society Scientific Sessions and the HFSA Annual Scientific Meeting

26 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Cytokinetics to Participate in Upcoming Investor Conferences

06 Sep 2022 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2022 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Reports Second Quarter 2022 Financial Results

04 Aug 2022 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics and The ALS Association Announce Release of Updated PRO-ACT Database Including Data From Cytokinetics’ Completed ALS Clinical Trials

04 Aug 2022 07:30:01 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Aug 2022 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics to Announce Second Quarter Results on August 4, 2022

21 Jul 2022 16:00:00 By Nasdaq GlobeNewswire

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

05 Jul 2022 16:00:00 By Nasdaq GlobeNewswire